Open AccessDENOSUMAB:
Author(s) -
Deepika Tikoo,
Mohit Gupta
Publication year - 2012
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2012.19.02.2027
Subject(s) - denosumab , medicine , rankl , activator (genetics) , osteoporosis , receptor , bone resorption , bone remodeling , osteoprotegerin , nuclear receptor , endocrinology , cancer research , transcription factor , biology , biochemistry , gene
Osteoporosis is the most common metabolic bone disease in developed countries. One of its major problems is the long termmorbidity and poor quality of life of patients. Receptor activator of nuclear factor-kB, its ligand and osteoprotegrin pathway plays an importantrole in bone remodeling. Receptor activator of nuclear factor-kB interacts with receptor activator of nuclear factor-kB ligand leading to activationof osteoclasts. Denosumab, a fully monoclonal antibody to receptor activator of nuclear factor-kB ligand prevents its binding to receptoractivator of nuclear factor-kB and can effectively suppress the bone loss in osteoporosis. Various clinical studies have shown that Denosumabhas good efficacy in decreasing bone resorption and has a favourable safety profile also.